EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 200 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Happy Holidays from the OncoLink Team December 7, 2023 Research with integrity – referencing work is way more than just... May 3, 2023 Help Desk for Oncologists Treating People with a Rare Leukemia Pays... February 2, 2023 Opinion: “There’s cause for optimism in 2021 and beyond” December 30, 2020 Load more HOT NEWS Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... How cancer hijacks cell death: a new view of metastasis Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens...
